Gorlin Syndrome and Cowden Syndrome.

IF 1.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Hiroyuki Goto, Chiharu Tateishi, Daisuke Tsuruta
{"title":"Gorlin Syndrome and Cowden Syndrome.","authors":"Hiroyuki Goto,&nbsp;Chiharu Tateishi,&nbsp;Daisuke Tsuruta","doi":"10.2302/kjm.2023-0010-IR","DOIUrl":null,"url":null,"abstract":"<p><p>Gorlin syndrome and Cowden syndrome are hereditary diseases that are characterized by multiple malignancies, cutaneous symptoms, and various other abnormalities. Both disorders are caused by a mutation of the gene that regulates cell proliferation and growth, resulting in tumorigenesis. Representative mutations are mutation in the patched 1 gene (PTCH1) in Gorlin syndrome and mutation in the phosphatase and tensin homolog deleted from chromosome 10 (PTEN) gene in Cowden syndrome. Making a diagnosis of these diseases in the early years of life is important because detection of malignancies at an early stage is linked to improved prognosis. Both Gorlin syndrome and Cowden syndrome have cutaneous findings in the early phase in childhood, and the role of dermatologists is therefore important. These diseases are generally diagnosed by clinical criteria, but some patients who do not meet the criteria need genetic examinations including a genetic diagnostic panel and next-generation sequencing. The most important treatment and management are detection and resection of malignancies in the early stage, and targeted therapies have recently been used for treatment of tumors and other symptoms in these diseases. Although evidence of the effectiveness of targeted therapies has been limited, they are promising therapeutic options and further clinical trials are needed in the future.</p>","PeriodicalId":46245,"journal":{"name":"KEIO JOURNAL OF MEDICINE","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"KEIO JOURNAL OF MEDICINE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2302/kjm.2023-0010-IR","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Gorlin syndrome and Cowden syndrome are hereditary diseases that are characterized by multiple malignancies, cutaneous symptoms, and various other abnormalities. Both disorders are caused by a mutation of the gene that regulates cell proliferation and growth, resulting in tumorigenesis. Representative mutations are mutation in the patched 1 gene (PTCH1) in Gorlin syndrome and mutation in the phosphatase and tensin homolog deleted from chromosome 10 (PTEN) gene in Cowden syndrome. Making a diagnosis of these diseases in the early years of life is important because detection of malignancies at an early stage is linked to improved prognosis. Both Gorlin syndrome and Cowden syndrome have cutaneous findings in the early phase in childhood, and the role of dermatologists is therefore important. These diseases are generally diagnosed by clinical criteria, but some patients who do not meet the criteria need genetic examinations including a genetic diagnostic panel and next-generation sequencing. The most important treatment and management are detection and resection of malignancies in the early stage, and targeted therapies have recently been used for treatment of tumors and other symptoms in these diseases. Although evidence of the effectiveness of targeted therapies has been limited, they are promising therapeutic options and further clinical trials are needed in the future.

Gorlin综合征和Cowden综合征。
Gorlin综合征和Cowden综合征是遗传性疾病,其特征是多种恶性肿瘤、皮肤症状和各种其他异常。这两种疾病都是由调节细胞增殖和生长的基因突变引起的,导致肿瘤发生。典型的突变是Gorlin综合征的补丁1基因(PTCH1)突变和Cowden综合征的10号染色体上的磷酸酶和紧张素同源物缺失(PTEN)基因突变。在生命早期对这些疾病进行诊断非常重要,因为早期发现恶性肿瘤与改善预后有关。Gorlin综合征和Cowden综合征在儿童早期都有皮肤表现,因此皮肤科医生的作用很重要。这些疾病通常是根据临床标准诊断的,但一些不符合标准的患者需要进行基因检查,包括基因诊断小组和下一代测序。最重要的治疗和管理是早期发现和切除恶性肿瘤,近年来靶向治疗已被用于治疗这些疾病的肿瘤和其他症状。尽管靶向治疗有效性的证据有限,但它们是有希望的治疗选择,未来需要进一步的临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
KEIO JOURNAL OF MEDICINE
KEIO JOURNAL OF MEDICINE MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
3.10
自引率
0.00%
发文量
23
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信